Posted from: Tuesday, May 31, 2016 - 04:34 PM - Present

Nuplazid Approved for Parkinson

April 29, 2016 – The U.S. Food and Drug Administration (FDA) approved Nuplazid™ (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Manufactured by Acadia Pharmaceuticals, the recommended dose of Nuplazid is 34mg (two 17mg tablets) once daily. Acadia plans on launching Nuplazid by the end of May and will be a limited distribution specialty medication.

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Thursday, March 23, 2017 - 09:23 AM.